Status:

WITHDRAWN

Efficacy of Pramipexole Extended Release in the Treatment of Essential Tremor

Lead Sponsor:

University of Pecs

Conditions:

Essential Tremor

Eligibility:

All Genders

18-80 years

Phase:

PHASE3

Brief Summary

Aim of the study is to perform a double-blind, crossover, placebo-controlled multicenter study evaluating the efficacy of pramipexole on essential tremor.

Detailed Description

Essential tremor is one of the most common movement disorders with the prevalence of 3-5% among the elderly population. Although its main clinical feature is the bilateral, predominantly postural-kine...

Eligibility Criteria

Inclusion

  • Diagnosis of ET has to be unambiguous based on the clinical diagnostic criteria.
  • Tremor has to be severe enough to produce disability.
  • Patients must sign a written informed consent according with the approval of the Regional Ethical Board of University of Pécs

Exclusion

  • Exclusion criteria are established in accordance to the guidelines of Elble et al3.
  • Presence of any medical conditions capable of producing tremor (e.g. hyperthyroidism, drug withdrawal, neuropathy, etc.).
  • Except for cogwheel phenomenon, the presence of any abnormal neurological signs (e.g. dystonia, myoclonus, ataxia, parkinsonism, cerebellar or pyramidal signs, etc.)
  • Atypical tremor appearance for ET (e.g. isolated vocal-cord tremor, orthostatic tremor, task-specific tremor, etc.)
  • Presence or suspicion of psychogenic tremor
  • Usage of medication capable of producing tremor (e.g. sympathomimetics, valproate, etc.)
  • Concomitant administration of any drugs potentially capable of improving ET (e.g. antiepileptics, beta-receptor blockers).
  • Previous neurosurgical treatment (e.g. deep brain stimulation or thalamotomy).
  • Presence of serious concomitant disorders capable of interfering with the study (e.g. heart failure, tumorous disorders, etc.)
  • Presence of any contraindication for pramipexole treatment (e.g. impulsive control disorder, known hypersensitivity to any components of the tablets, etc.)

Key Trial Info

Start Date :

December 1 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2018

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT01441284

Start Date

December 1 2017

End Date

December 1 2018

Last Update

May 8 2017

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Department of Neurology, University of Pécs

Pécs, Baranya, Hungary, H-7623

2

Kaposi Mór County Hospital

Kaposvár, Somogy County, Hungary, H-7400